Durvalumab and Oleclumab in Resectable PDAC
Durvalumab and Oleclumab in Resectable PDAC
Recruiting · NCT06060405 · Registry updated 2026-06-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab and Oleclumab in Resectable PDAC | pancreatic ductal adenocarcinoma | Recruiting | Phase 2 | 2026-06-23 | NCT06060405 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Health Network, Toronto | 417 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Princess Margaret Cancer Centre | Toronto | Canada | 145 |